Drug Profile
Dipyridamole/prednisolone
Alternative Names: CRx-102; CRx-102 aligned release; Prednisolone/dipyridamole; Prednisolone/dipyridamole aligned release; Synavive; Synavive AR; Z-102Latest Information Update: 01 Aug 2016
Price :
$50
*
At a glance
- Originator CombinatoRx
- Developer CombinatoRx; Zalicus
- Class Anti-inflammatories; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienetriols; Pyrimidines; Small molecules
- Mechanism of Action Cyclic GMP phosphodiesterase inhibitors; Glucocorticoid receptor agonists; Immunosuppressants; Nucleoside transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation; Osteoarthritis; Periodontal disorders; Rheumatoid arthritis
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals
- 13 Sep 2012 Discontinued - Phase-II for Rheumatoid arthritis in Romania (PO)